JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on February 8, 2005; DOI: 10.1124/jpet.104.082560


0022-3565/05/3133-1136-1149$20.00
JPET 313:1136-1149, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.082560v1
313/3/1136    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yassen, A.
Right arrow Articles by Danhof, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yassen, A.
Right arrow Articles by Danhof, M.

NEUROPHARMACOLOGY

Pharmacokinetic-Pharmacodynamic Modeling of the Antinociceptive Effect of Buprenorphine and Fentanyl in Rats: Role of Receptor Equilibration Kinetics

Ashraf Yassen, Erik Olofsen, Albert Dahan, and Meindert Danhof

Leiden/Amsterdam Center for Drug Research, Division of Pharmacology, Gorlaeus Laboratory, Leiden, The Netherlands (A.Y., M.D.); and Department of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands (E.O., A.D.)

The objective of this investigation was to characterize the pharmacokinetic/pharmacodynamic correlation of buprenorphine and fentanyl for the antinociceptive effect in rats. Data on the time course of the antinociceptive effect following intravenous administration of buprenorphine or fentanyl was analyzed in conjunction with plasma concentrations by nonlinear mixed-effects analysis. For fentanyl, the pharmacokinetics was described on the basis of a two-compartment pharmacokinetic model. For buprenorphine, a three-compartment pharmacokinetic model best described the concentration time course. To explain time dependencies in pharmacodynamics of buprenorphine and fentanyl, a combined effect compartment/receptor binding model was applied. A log logistic probability distribution model is proposed to account for censored tail-flick latencies. The model converged, yielding precise estimates of the parameters characterizing hysteresis. The results show that onset and offset of the antinociceptive effect of both buprenorphine and fentanyl is mainly determined by biophase distribution. The keo was 0.024 min–1 [95% confidence interval (CI): 0.018–0.030 min–1] and 0.123 min–1 (95% CI: 0.095–0.151 min–1) for buprenorphine and fentanyl, respectively. On the other hand, part of the hysteresis in the buprenorphine pharmacodynamics could be explained by slow receptor association/dissociation kinetics. The koff was 0.073 min–1 (95% CI: 0.042–0.104 min–1) and kon was 0.023 ml/ng/min (95% CI: 0.013–0.033 ml/ng/min). Fentanyl binds instantaneously to the OP3 receptor because no reasonable values for kon and koff were obtained with the dynamical receptor model. In contrast to earlier reports in the literature, the findings of this study show that the rate-limiting step in the onset and offset of buprenorphine's antinociceptive effect is distribution to the brain.


Received December 21, 2004; accepted February 3, 2005.

Address correspondence to: Dr. Meindert Danhof, Leiden/Amsterdam Center for Drug Research, Division of Pharmacology, Gorlaeus Laboratories, P.O. Box 9502, 2300 RA Leiden, The Netherlands. E-mail: m.danhof{at}lacdr.leidenuniv.nl




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
A. Yassen, J. Kan, E. Olofsen, E. Suidgeest, A. Dahan, and M. Danhof
Pharmacokinetic-Pharmacodynamic Modeling of the Respiratory Depressant Effect of Norbuprenorphine in Rats
J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 598 - 607.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. Yassen, J. Kan, E. Olofsen, E. Suidgeest, A. Dahan, and M. Danhof
Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of the Respiratory-Depressant Effect of Buprenorphine and Fentanyl in Rats
J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 682 - 692.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
A. Dahan, A. Yassen, R. Romberg, E. Sarton, L. Teppema, E. Olofsen, and M. Danhof
Buprenorphine induces ceiling in respiratory depression but not in analgesia
Br. J. Anaesth., May 1, 2006; 96(5): 627 - 632.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.